On the stock market since 2005, it operates in the world of health and science. It has 11,050 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 17% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $609M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 18% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 17% a year on average.
There is $2.0B in the vault; even if every debt were paid off, $609M would remain.
The company’s market value is 40 times its annual profit. Even a small disappointment could hit the price hard.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, DXCM sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: DXCM is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.